1. Definition of healthy ranges for alanine aminotransferase levels: a 2020 update. (March 2021) Authors: Valenti, L.; Pelusi, S.; Bianco, C.; Ceriotti, F.; Berzuini, A.; Prat, L. Iogna; Trotti, R.; Baselli, G.; D'Ambrosio, R.; Colombo, M.; Tsochatzis, E.; Fraquelli, M.; Prati, D. Journal: Digestive and liver disease Issue: Volume 53:(2021)Supplement 1 Page Start: S4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Diabetes and DAAs. (February 2020) Authors: Dalbeni, A.; Faccincani, D.; Bevilacqua, M.; Cattazzo, F.; Mantovani, A.; Mantovani, A.; Ieluzzi, D.; Paon, V.; Prat, L. Iogna; Sacerdoti, D. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Effects of DAAs (direct-acting antivirals) on cardiac function and structure in hepatitis c (HCV) patients with low-mild liver fibrosis. (February 2019) Authors: Dalbeni, A.; Romano, S.; Bevilacqua, M.; Imbalzano, E.; Piccoli, A.; Mantovani, A.; Benati, M.; Montagnana, M.; Torin, G.; Monaco, C.; Donato, A.; Prat, L. Iogna; Tagetti, A.; Paon, V.; Ribichini, F.; Minuz, P.; Fava, C. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 1 Page Start: e58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Validation of elastography criteria and cACLD Risk Model for diagnosis of compensated Advanced Chronic Liver Disease (cACLD) in NAFLD patients. (March 2023) Authors: Liguori, A.; Zoncapè, M.; Roccarina, D.; Viceconti, N.; Sciarra, A.; Beschi, R.; Prat, L. Iogna; Mantovani, A.; Clancy, J.; Goyale, A.; Grieco, A.; Miele, L.; Tsochatzis, E.A. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗